Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 15.84% is 123% above its 5-year average of 7.11%, near the high end of its 5-year range (-46.15%–33.48%).
19.18% below its 12-month average of 19.60%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 33.48%.
EBITDA MARGIN
15.84%
EBITDA MARGIN AVG TTM
19.60%
EBITDA MARGIN AVG 3Y
7.57%
EBITDA MARGIN AVG 5Y
7.11%
EBITDA MARGIN AVG 10Y
6.39%
EBITDA MARGIN AVG 15Y
7.17%
EBITDA MARGIN AVG 20Y
6.20%
CURRENT VS TTM AVG
-19.18%
CURRENT VS 3Y AVG
+109.23%
CURRENT VS 5Y AVG
+122.87%
CURRENT VS 10Y AVG
+148.01%
CURRENT VS 15Y AVG
+121.05%
CURRENT VS 20Y AVG
+155.46%
ImmuCell Corporation
Market Cap
$88.21M
EBITDA Margin
15.84%
TTM Avg
19.60%
3Y Avg
7.57%
5Y Avg
7.11%
Market Cap
$87.48M
EBITDA Margin
-8103.88%
TTM Avg
-7583.93%
3Y Avg
-8667.05%
5Y Avg
-7944.60%
Market Cap
$90.41M
EBITDA Margin
-19.79%
TTM Avg
-29.84%
3Y Avg
-150.95%
5Y Avg
-150.95%
Market Cap
$85.90M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$85.18M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$84.87M
EBITDA Margin
-4911.29%
TTM Avg
-4911.29%
3Y Avg
-4895.51%
5Y Avg
-4835.22%
Market Cap
$84.52M
EBITDA Margin
31.45%
TTM Avg
-14.67%
3Y Avg
-906.21%
5Y Avg
-1050.55%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ImmuCell Corporation (ICCC) | $88.21M | 15.84% | 19.60% | 7.57% | 7.11% |
| CareCloud, Inc. (CCLD)vs › | $87.75M | 23.63% | 23.21% | 8.97% | 9.09% |
| Cardiff Oncology, Inc. (CRDF)vs › | $87.48M | -8103.88% | -7583.93% | -8667.05% | -7944.60% |
| Conexeu Sciences Inc. (CNXU)vs › | $86.43M | N/A | N/A | N/A | N/A |
| Equillium, Inc. (EQ)vs › | $90.41M | -19.79% | -29.84% | -150.95% | -150.95% |
| Cognition Therapeutics, Inc. (CGTX)vs › | $85.90M | N/A | N/A | N/A | N/A |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $85.18M | N/A | N/A | N/A | N/A |
| Humacyte, Inc. (HUMA)vs › | $84.87M | -4911.29% | -4911.29% | -4895.51% | -4835.22% |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $84.52M | 31.45% | -14.67% | -906.21% | -1050.55% |
| electroCore, Inc. (ECOR)vs › | $92.14M | -35.83% | -39.56% | -111.97% | -250.85% |
Gross Margin
40.3%
EBITDA Margin
15.8%
Operating Margin
12.6%
Net Margin
2.6%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 33.48% |
| 2026-03-31 | 24.11% |
| 2025-12-31 | 8.50% |
| 2025-09-30 | 12.70% |
| 2025-06-30 | 19.21% |
| 2025-03-31 | 22.23% |
| 2024-12-31 | 16.71% |
| 2024-09-30 | 1.67% |
| 2024-06-30 | -13.08% |
| 2024-03-31 | 5.06% |
| 2023-12-31 | -6.24% |
| 2023-09-30 | -8.96% |
| 2023-06-30 | -16.97% |
| 2023-03-31 | -46.15% |
| 2022-12-31 | -26.32% |
| 2022-09-30 | 0.32% |
| 2022-06-30 | 0.27% |
| 2022-03-31 | 19.87% |
| 2021-12-31 | 13.76% |
| 2021-09-30 | 17.32% |
| 2021-06-30 | 18.51% |
| 2021-03-31 | 6.03% |
| 2020-12-31 | -0.55% |
| 2020-09-30 | 9.38% |
| 2020-06-30 | -3.99% |
| 2020-03-31 | 15.41% |
| 2019-12-31 | 8.80% |
| 2019-09-30 | 4.63% |
| 2019-06-30 | 0.82% |
| 2019-03-31 | 18.91% |
| 2018-12-31 | -12.19% |
| 2018-09-30 | 10.84% |
| 2018-06-30 | 3.05% |
| 2018-03-31 | 3.70% |
| 2017-12-31 | -4.79% |
| 2017-09-30 | -13.55% |
| 2017-06-30 | -3.02% |
| 2017-03-31 | 32.07% |
| 2016-12-31 | 14.95% |
| 2016-09-30 | 12.88% |
| 2016-06-30 | 9.93% |
| 2016-03-31 | 29.20% |
| 2015-12-31 | 22.65% |
| 2015-09-30 | 30.83% |
| 2015-06-30 | 17.49% |
| 2015-03-31 | 30.19% |
| 2014-12-31 | 14.28% |
| 2014-09-30 | 8.20% |
| 2014-06-30 | -22.28% |
| 2014-03-31 | 6.04% |
| 2013-12-31 | -5.65% |
| 2013-09-30 | -5.03% |
| 2013-06-30 | 9.02% |
| 2013-03-31 | 22.99% |
| 2012-12-31 | 7.62% |
| 2012-09-30 | 0.82% |
| 2012-06-30 | 12.35% |
| 2012-03-31 | 22.43% |
| 2011-12-31 | 8.95% |
| 2011-09-30 | -9.53% |
| 2011-06-30 | -26.09% |
| 2011-03-31 | 5.78% |
| 2010-12-31 | -10.53% |
| 2010-09-30 | -27.93% |
| 2010-06-30 | 5.54% |
| 2010-03-31 | 2.37% |
| 2009-12-31 | 1.87% |
| 2009-09-30 | 6.06% |
| 2009-06-30 | -21.23% |
| 2009-03-31 | 2.01% |
| 2008-12-31 | -15.26% |
| 2008-09-30 | -48.95% |
| 2008-06-30 | -35.66% |
| 2008-03-31 | 10.33% |
| 2007-12-31 | 10.67% |
| 2007-09-30 | 49.84% |
| 2007-06-30 | -1.69% |
| 2007-03-31 | 33.07% |
| 2006-09-30 | 28.48% |
| 2006-06-30 | 11.75% |
| 2006-03-31 | 38.08% |
| 2005-12-31 | 31.22% |
| 2005-09-30 | 31.33% |
| 2005-06-30 | 26.51% |
| 2005-03-31 | 35.68% |
| 2004-12-31 | 6.72% |
| 2004-09-30 | 5.52% |
| 2004-06-30 | -7.52% |
| 2004-03-31 | 27.33% |
| 2003-12-31 | -18.06% |
| 2003-09-30 | -1.04% |
| 2003-06-30 | -24.22% |
| 2003-03-31 | 12.92% |
| 2002-12-31 | 22.67% |
| 2002-09-30 | 6.75% |
